B Cell Acute Lymphoblastic Leukemia B All clinical trials

Explore recruiting b cell acute lymphoblastic leukemia b all clinical trials.

Recruiting b cell acute lymphoblastic leukemia b all studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Acute Lymphoblastic Leukemia B All trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia

Spain, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A modular Phase I/II, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of AZD4512 monotherapy or in combination with anticancer agent(s) in participants with Acute Lymphoblastic Leukemia

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Germany, Italy, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Greece, Netherlands, Sweden, France, Italy, Spain +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy

Belgium, Norway, Spain, France, Netherlands, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

France, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

B Cell Acute Lymphoblastic Leukemia B All trials by city

B Cell Acute Lymphoblastic Leukemia B All clinical trials

Recruiting b cell acute lymphoblastic leukemia b all studies right now

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Orphan Indications for CD19 Redirected Autologous T Cells

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL